Androxal Passes First 'Testes'; Next Phase III Enrolled by May
Repros Therapeutics Inc.'s first pivotal study, called ZA-301, with the hypogonadism therapy Androxal (enclomiphene) hit both of its primary endpoints – testosterone and sperm count – in the intent-to-treat population, as mandated by the FDA, and CEO Joseph Podolski said the $2 billion demand for such therapies could get bigger than the market for erectile dysfunction drugs.
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter